China Money Network
Login
Join

Ark BioPharmaceutical Receives Approval for Azstarys in China for ADHD Treatment

  • January 6, 2026 — 18:30 CST

This Data Is Locked!

This area is available only to Subscribers.

Ark Biopharmaceutical, now known as Ark BioPharmaceutical, has received approval from China's NMPA for their drug Azstarys to treat ADHD in patients 6 years and... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: